Study guide

6.2 FDA Approval, Recalls, and OTC vs Rx

Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy

2 Connecticut Regulatory Structure

2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)

3 Pharmacist Licensure, Interns, PIC, and CE

3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education

4 Technicians and Non-Pharmacist Personnel

4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff

5 Discipline, Impairment, and Unlicensed Practice

5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals

6 Federal Drug Law Foundations

6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA

7 Federal Controlled Substances

7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal

8 Prescription Issuance in Connecticut

8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate

9 Refills, Partial Fills, and Opioid Limits

9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)

10 Administration, CDTM, and Standing Orders

10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception

11 Counseling, Confidentiality, and Returns

11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back

12 Corresponding Responsibility and DUR

12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing

13 Transfers, Labeling, Packaging, and Delivery

13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs

14 CPMRS, Substitution, and Nonprescription Drugs

14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs

15 Ordering, Records, and Inventories

15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII

16 Storage, Security, and Hazardous Drugs

16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs

17 Compounding and Central Fill

17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing

18 Pharmacy Permits and Practice Settings

18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline

6.2 FDA Approval, Recalls, and OTC vs Rx

Key Takeaways Explain This Topic AI

Hatch-Waxman (1984) created the ANDA under FDCA § 505(j) for small-molecule generics; a full NDA remains § 505(b); biologics are licensed under PHS Act § 351, not as ANDAs.

The Orange Book lists NDA/ANDA products and therapeutic-equivalence codes (A/AB versus B); the Purple Book lists licensed biologics, biosimilars, and interchangeable biologics.

Class I recall: reasonable probability of serious adverse health consequences or death, generally consumer-level; Class II: temporary or reversible harm or remote serious harm, generally retail; Class III: not likely to cause harm, generally wholesale.

A market withdrawal is not a recall. Most drug recalls are manufacturer-initiated; FDA classifies and oversees them under 21 CFR Part 7 and may request or order a recall where statute allows.

When a recall hits, quarantine matching lots, stop dispensing them, and follow the firm's and FDA's instructions—Class I consumer-level notices generally include patient contact. CT may be stricter; more-restrictive wins.

Last updated: August 2026

Why approval status and recall class are tested

Quick Answer: An ANDA under Hatch-Waxman (FDCA § 505(j)) is how FDA approves a small-molecule generic; biologics are licensed under PHS Act § 351 . Look up tablets in the Orange Book (A/AB versus B therapeutic-equivalence codes) and biologics in the Purple Book (biosimilar versus interchangeable). Class I recalls carry a reasonable probability of serious harm or death; Class II temporary or remote serious harm; Class III not likely to cause harm. Most recalls are manufacturer-initiated ; FDA classifies and oversees. Quarantine the lots and follow the notice.

NABP 2.5 and the DSCSA/FDCA overlay both assume you can tell an approved generic from a biologic, and a Class I recall from a market withdrawal. Connecticut substitution ( CGS § 20-619 , Chapter 14) will teach how a pharmacist substitutes; this section teaches the federal listing those statutes point to. FDA.gov and 21 CFR Part 7 are the primary sources. Connecticut Drug Control can still cite you for leaving recalled stock in active inventory. CT may be stricter; more-restrictive wins.

NDA, ANDA, and Hatch-Waxman

A New Drug Application (NDA) under FDCA § 505(b) (21 U.S.C. § 355(b)) is the full federal package that demonstrates safety and effectiveness for a specified use. A 505(b)(1) NDA contains the sponsor's own investigations. A 505(b)(2) NDA may rely in part on studies not conducted by the applicant (published literature or FDA's findings on a listed drug). Neither pathway is 'generic approval.'

The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) created the Abbreviated New Drug Application (ANDA) under § 505(j). An ANDA does not repeat the innovator's clinical program. The applicant must show that the generic is the same as the reference listed drug (RLD) in active ingredient, dosage form, strength, route, and labeling (with permitted differences), and that it is bioequivalent . Approval of an ANDA is what puts a substitutable small-molecule generic on the market.

Biologics are licensed under § 351 of the Public Health Service Act (42 U.S.C. § 262), not under an NDA. A biosimilar is highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency. An interchangeable biologic is a biosimilar that meets the extra PHS Act standard: it can be expected to produce the same clinical result in any given patient, and for a product administered more than once, the risk of alternating or switching is not greater than using the reference without switching. Insulin and certain other proteins that once sat in the Orange Book transitioned to biologics licenses on March 23, 2020 and now live in the Purple Book.

Federal listing: Orange Book versus Purple Book

Book What it lists Pathway Substitution signal

Orange Book ( Approved Drug Products with Therapeutic Equivalence Evaluations ) Small-molecule drugs approved under FDCA § 505 (NDAs and ANDAs) ANDA 505(j); TE codes A-rated (commonly AB ) products are therapeutically equivalent to the RLD; B-rated are not

Purple Book (database of licensed biological products) Biologics licensed under PHS Act § 351, including biosimilars and interchangeables 351(k) biosimilar / interchangeable Biosimilarity is not automatic pharmacy substitution; interchangeability is the federal substitution designation

Do not look up a monoclonal antibody in the Orange Book, and do not look up a hydrochlorothiazide tablet in the Purple Book. Connecticut will decide how a pharmacist substitutes under CGS § 20-619 ; the federal books tell you whether FDA has even made a therapeutic-equivalence or interchangeability finding. Chapter 14 goes deeper on state substitution mechanics.

Rx versus OTC at the counter

FDCA § 503(b) still divides human drugs into two classes. Prescription (Rx-only) drugs are those that are not safe for use except under practitioner supervision, or that are limited to prescription use by approved labeling. OTC drugs can be labeled with adequate directions for a layperson to use safely. Moving a drug from Rx to OTC is a federal FDA decision (typically a supplemental NDA or an OTC monograph change), not a Connecticut Commission vote.

Consequences at a Connecticut bench:

Dispensing an Rx-only product without a valid prescription misbrands it under § 502

Stocking an OTC product is still subject to adulteration and misbranding, to CMEA limits if it contains pseudoephedrine (section 6.3; full BTC rules in Chapter 14), and to Connecticut nonlegend-drug permit rules (Chapter 419 / CGS § 20-624)

A pharmacist cannot 'switch' an Rx drug to OTC because the patient asked, and cannot refuse to sell a lawfully marketed OTC solely because 'Connecticut has not approved it'

The tighter of FDA class and Connecticut retail-drug rules controls the sale.

Recalls: Class I, II, and III

FDA classifies recalls by risk. 21 CFR Part 7 and FDA's current recall pages (definitions current as of March 2026; consumer explainer current as of May 2026) use these definitions:

Class FDA definition Typical depth Patient use until told otherwise

Class I Reasonable probability that use or exposure will cause serious adverse health consequences or death Generally consumer level; urgent removal Follow the recalling firm's and FDA's instructions; usually stop use of the affected lots

Class II Use or exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote Generally retail level Patients may continue unless the recalling company or FDA directs otherwise

Class III Use or exposure is not likely to cause adverse health consequences (minor labeling, packaging, or dating defects) Generally wholesale level Continue unless directed otherwise

A market withdrawal is not a recall. It is a firm's removal or correction of a minor violation that would not be subject to FDA legal action (for example, isolated tampering without evidence of a manufacturing or distribution problem). Do not treat a market withdrawal as a Class III recall on the exam.

Who starts the recall. Most drug recalls are manufacturer-initiated (voluntary). FDA may request a recall, classifies it, and oversees the strategy and effectiveness under 21 CFR Part 7. FDA may order a recall where statute allows, and can seize product, seek an injunction, or publicize if a voluntary recall is ineffective. The pharmacist's duty does not wait for a DCP letter. A manufacturer letter and an FDA Enforcement Report are enough to act.

Pharmacist duty when a recall hits

When a notice names NDCs, lots, or serials that you stock or have dispensed:

Match the NDC, lot, or serial against on-hand inventory, including robots, will-call, night cabinets, and compounding stock

  • Quarantine affected packages immediately; do not leave them in active canisters with a sticky note
  • Stop dispensing the affected lots

Identify patients who received those lots when the recall is consumer-level (especially Class I ) and follow the recalling firm's and FDA's contact instructions

  • Document what you found, whom you notified, and how you disposed of or returned the stock
  • Notify the pharmacist manager / PIC and follow the pharmacy's written recall procedure
  • Check FDA Enforcement Reports if the manufacturer letter is incomplete

A Class II or III recall generally does not require calling every patient unless the notice says so. A Class I consumer-level recall does . Telling a patient to 'keep taking it until DCP inspects us' is the wrong instinct. Stopping a chronic medicine without a plan can also harm the patient—follow the notice, then coordinate a replacement lot or an alternative with the prescriber.

Scenario: two notices, one week

A Stamford pharmacy receives a manufacturer Class I notice for a lot of injectable product with a reasonable probability of bacterial contamination. The same week, a wholesaler announces a Class III recall for a bottle whose outer carton has a transposed NDC but the inner label is correct. The pharmacist must pull and quarantine the injectable lots, identify patients who received them, and follow the Class I instructions. The carton-only Class III product is pulled from the shelf per the notice, but there is no automatic duty to phone every patient. Treating both events as 'just Class III because nobody died yet' fails the FDA classification. Leaving either lot in the robot is a quality failure DCP can cite even if FDA never visits.

Connecticut may add quarantine, documentation, or patient-notice expectations on top of FDA's floor. CT may be stricter; more-restrictive wins.

Official anchors

FDA Orange Book preface — NDA/ANDA listing and Hatch-Waxman.

FDA Purple Book background — biosimilarity and interchangeability.

FDA recall definitions and Understanding Drug Recalls — Class I/II/III and FDA's oversight role.